Ilumya

Approved Indications

Ilumya is specifically indicated for the treatment of moderate-to-severe plaque psoriasis in adults. Plaque psoriasis is a chronic autoimmune condition that causes skin cells to build up rapidly, resulting in thick, red, and scaly patches that can be itchy or painful.

Treatment Criteria

Healthcare providers typically prescribe this medication for patients who may benefit from the following types of treatment:

• Systemic therapy: Medications that travel through the bloodstream to treat the entire body, rather than just the skin surface.
• Phototherapy: Medical treatments that involve exposing the skin to controlled ultraviolet (UV) light.

Ilumya is intended for long-term management of plaque psoriasis symptoms. It is not currently approved for use in children or for the treatment of other conditions, such as psoriatic arthritis.

Mechanism of Action

Ilumya (tildrakizumab-asmn) is a monoclonal antibody that belongs to a class of medications known as interleukin inhibitors. It is designed to target and block a specific protein in the body called interleukin-23 (IL-23).

In a healthy body, IL-23 is a cytokine—a chemical messenger—that helps regulate the immune system's response to infection. However, in people with moderate-to-severe plaque psoriasis, the body produces an excess of IL-23. This overabundance triggers an overactive immune response, leading to:

• Chronic inflammation within the skin.
• An accelerated life cycle of skin cells, which causes them to build up rapidly on the surface and form thick, scaly plaques.

Ilumya works by binding specifically to the p19 subunit of the IL-23 protein. By doing so, it prevents IL-23 from attaching to its receptors on the surface of immune cells. This action interrupts the inflammatory signaling pathway, which helps to normalize the immune response, reduce skin inflammation, and slow down the excessive production of skin cells. Over time, this process helps clear existing plaques and prevents new ones from forming.

Common Side Effects

The most frequently reported side effects of Ilumya are generally mild. These may include:

• Upper respiratory infections: Such as the common cold, sinus infections, or sore throat.
• Injection site reactions: Redness, pain, itching, or swelling where the medication was injected.
• Diarrhea: Loose or frequent stools.

Serious Side Effects

While less common, Ilumya can cause serious side effects that require immediate medical attention. These include:

• Serious infections: Because Ilumya affects the immune system, it may increase the risk of infections. Symptoms can include fever, sweats, chills, muscle aches, cough, shortness of breath, or warm, red, or painful skin sores.
• Severe allergic reactions: Signs of a serious reaction include hives, swelling of the face, eyelids, lips, or tongue, chest tightness, or difficulty breathing.
• Tuberculosis (TB): Ilumya may reactivate a latent TB infection. Healthcare providers typically test for TB before starting treatment.

If you experience signs of an infection or a severe allergic reaction, contact a healthcare professional immediately.

Infections

Ilumya is a medication that affects the immune system, which may decrease the body's ability to fight infections. This can increase the risk of developing new infections or worsening existing ones. Treatment should generally not be started in individuals with a clinically important active infection until the infection resolves or is adequately treated.

Signs of a potential infection include:

• Fever, sweats, or chills
• Muscle aches
• Cough or shortness of breath
• Burning during urination
• Warm, red, or painful skin sores

Tuberculosis Screening

Before starting Ilumya, healthcare providers typically screen patients for tuberculosis (TB). If a patient has latent TB, treatment for the infection is usually started before beginning Ilumya. Patients should be monitored for signs and symptoms of TB during and after treatment.

Hypersensitivity Reactions

Serious allergic reactions, such as angioedema and urticaria (hives), have occurred in some people taking Ilumya. If a serious hypersensitivity reaction occurs, the medication should be discontinued immediately and appropriate medical therapy started.

Vaccinations

It is recommended that all age-appropriate immunizations be completed before starting treatment with Ilumya. While using this medication, live vaccines should be avoided, as the immune system's response may be altered.

Pregnancy

Data regarding the use of Ilumya in pregnant women is limited. While animal studies have not shown evidence of harm to a developing fetus at high doses, these results do not always predict how the drug will affect humans. Because Ilumya is a monoclonal antibody, it is expected to cross the placenta, particularly during the third trimester of pregnancy.

Healthcare providers typically recommend using this medication during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are pregnant or planning to become pregnant, consult your doctor to discuss your treatment options.

Breastfeeding

It is currently unknown whether Ilumya passes into human breast milk or if it has any effect on a nursing infant or milk production. Because many drugs are excreted in human milk, caution is advised. Individuals who are breastfeeding or planning to breastfeed should talk with their healthcare provider to weigh the benefits of breastfeeding against the potential risks of the medication.

Available Forms

Ilumya is supplied as a liquid solution for subcutaneous injection. It is available in the following delivery format:

• Single-dose prefilled syringe: This device is intended for one-time use and is administered by a healthcare professional.

The medication is injected into the fatty tissue just beneath the skin, typically in areas such as the abdomen, thighs, or upper arms.

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Ilumya on March 21, 2018. It was approved as a humanized interleukin-23 (IL-23) antagonist for the treatment of chronic skin conditions.

Approved Indications

Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for:

• Systemic therapy (medications that work throughout the body)
• Phototherapy (light treatments)

Regulatory Status

Ilumya is a prescription-only medication. At this time, the FDA does not require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for this drug. It is administered by a healthcare professional via subcutaneous injection.

Insurance and Out-of-Pocket Costs

The price you pay for Ilumya depends largely on your health insurance plan. Most commercial insurance plans, Medicare, and Medicaid provide some level of coverage for this medication. However, your specific out-of-pocket costs will be determined by your plan's deductible, copayments, or coinsurance requirements. Because Ilumya is a biologic medication, it is often processed through a medical benefit rather than a pharmacy benefit.

Administration Fees

Ilumya is administered by a healthcare professional in a medical office or clinic. Consequently, the total cost of treatment may include fees for the office visit and the professional administration of the injection, in addition to the cost of the drug itself.

Financial Assistance Programs

There are options available to help manage the cost of Ilumya for eligible patients:

• Copay Savings Cards: Patients with commercial insurance may be eligible for manufacturer programs that reduce out-of-pocket costs to a minimal amount.
• Patient Assistance: For individuals who are uninsured or have limited financial resources, programs may be available to provide the medication at no cost or a reduced rate.
• Support for Government Insurance: Patients with Medicare or other government-funded insurance may need to seek assistance through independent charitable foundations if they face high costs.

At this time, there are no biosimilar versions of Ilumya available. Biosimilars are typically lower-cost alternatives to biologic drugs, but until one is approved and released, the brand-name medication remains the only option for this specific therapy.